TympaHealth is a technology company.
TympaHealth has raised $31.0M across 2 funding rounds.
TympaHealth has raised $31.0M in total across 2 funding rounds.
TympaHealth is a London-based healthtech company founded in 2017 that develops the Tympa system, a portable, all-in-one platform for comprehensive ear and hearing health assessments.[2][4][5] The product integrates HD digital otoscopy, microsuction wax removal, 4-frequency hearing checks (500Hz to 4kHz), secure cloud storage, and remote specialist review, enabling clinicians to deliver services in community settings like pharmacies, care homes, GP clinics, opticians, and domiciliary care.[1][2][3][4] It serves healthcare professionals and patients facing hearing loss—a condition affecting 14% of Americans and linked to dementia risk, falls, and social isolation—by democratizing access, reducing unnecessary hospital visits, and supporting early detection in cost-effective ways.[1][3][4] With CE-marking, FDA registration, NHS/GDPR/DTAC/HIPAA compliance, and over 40,000 monthly patient appointments plus 250,000+ total patients seen, TympaHealth shows strong growth across UK NHS trusts, private sectors, and expansion into the US.[3][4]
TympaHealth emerged from the vision of Dr. Krishan Ramdoo, a doctor whose background and determination to transform ear and hearing healthcare led to the company's founding in 2017 in London, UK.[2][5] The idea addressed systemic access barriers, bringing ENT expertise to community settings amid rising demand for efficient care, with the portable smartphone-enabled otoscope and app developed as the world's first all-in-one hearing health assessment tool.[1][5][7] Early traction came through adoption in NHS trusts for triage and pilots like the 2022 South West London ICS project, which streamlined pathways via community pharmacies, reducing wait times and costs while serving over 250,000 patients to date.[3] Pivotal endorsements from figures like NHS Chairman Lord David Prior and former Apple Health executive Anil Sethi highlighted its patient-centric innovation, fueling expansion into private sectors and research-driven advances.[1]
TympaHealth stands out in digital health through these key strengths:
TympaHealth rides the digital health wave of out-of-hospital care, leveraging portable diagnostics and AI/ML to shift ENT services from overburdened hospitals to communities amid aging populations and hearing loss epidemics.[1][2][5] Timing aligns with post-pandemic telehealth acceleration and NHS elective care backlogs, where pilots demonstrate cost savings and faster triage—e.g., pharmacy-based pathways cut waits versus traditional models.[3] Favorable market forces include US expansion potential (14% hearing loss prevalence) and global dementia prevention focus, positioning it in expert collections like CB Insights' Digital Health alongside audiology innovators.[1][2][6] It influences the ecosystem by training non-specialists, fostering peer-reviewed advances, and partnering with NHS/pharmacies, democratizing care and reducing isolation/falls risks.[1][4]
TympaHealth is poised for scaled US growth and international markets like the Netherlands, building on HIPAA compliance, pharmacy partnerships, and 40,000+ monthly assessments.[3][4][6] Trends in AI-enhanced diagnostics, value-based care, and preventive health (e.g., dementia risk reduction) will amplify its momentum, potentially via deeper NHS integrations or acquisitions.[1][5] Its influence may evolve from UK pioneer to global standard-setter, empowering communities and clinicians while advancing research—exemplifying how targeted healthtech unlocks accessible, efficient care for all.[1][4]
TympaHealth has raised $31.0M in total across 2 funding rounds.
TympaHealth's investors include Highland Capital Partners, Octopus Ventures, Sonder Capital, Anil Sethi, Martin Varsavsky, Maurice Ferre, Atomic, Fusion Fund, Pareto Holdings, Jack Schuler, Kimberly Vogel, Shervin Pishevar.
TympaHealth has raised $31.0M across 2 funding rounds. Most recently, it raised $23.0M Series A in April 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2023 | $23.0M Series A | Highland Capital Partners, Octopus Ventures, Sonder Capital, Anil Sethi, Martin Varsavsky, Maurice Ferre | |
| Feb 1, 2022 | $8.0M Seed | Atomic, Fusion Fund, Highland Capital Partners, Octopus Ventures, Pareto Holdings, Sonder Capital, Jack Schuler, Kimberly Vogel, Martin Varsavsky, Maurice Ferre, Shervin Pishevar |